Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. / Bennedsgaard, Kristine; Ventzel, Lise; Themistocleous, Andreas C.; Bennett, David L.; Jensen, Anders B.; Jensen, Anni R.; Andersen, Niels T.; Jensen, Troels S.; Tankisi, Hatice; Finnerup, Nanna B.

I: Cancer Medicine, Bind 9, Nr. 14, 07.2020, s. 5114-5123.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{624db4f43e6d4c408388c870f4b3242f,
title = "Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy",
abstract = "Background: The aim of this study was to assess chemotherapy-induced polyneuropathy (CIPN) 5 years after adjuvant chemotherapy in patients with breast and colorectal cancer. The association of CIPN with quality of life, anxiety, and depression was analyzed. Methods: Of a set of 100 patients with breast cancer and of 74 with colorectal cancer who had undergone surgery and adjuvant chemotherapy in 2011-2012, 80 and 52 patients alive, respectively, were included together with two reference groups of 249 breast cancer patients and 83 colorectal cancer patients who had undergone surgery only. All patients were sent a questionnaire on alcohol consumption, smoking habits, comorbidity, medicine consumption, and oxaliplatin-specific questions, as well as the Michigan Neuropathy Screening Instrument questionnaire (MNSIq), the Douleur Neuropathique 4 Questions (DN4q), the EQ-5D, and the Hospital Anxiety and Depression Scale. Possible polyneuropathy was defined as the presence of numbness and/or tingling in the feet, secondly as a score of ≥4 on the MNSIq. Possible painful polyneuropathy was defined as pain in both feet and a score ≥3 on the DN4q. Results: The prevalence of possible polyneuropathy defined by numbness and/or tingling in the feet was 38.8% (28.1-50.3) after adjuvant docetaxel and 57.7% (43.2-71.3) after adjuvant oxaliplatin, with no significant difference from a previous 1-year follow-up (P >.35). Fewer had possible polyneuropathy as defined by the MNSIq. Patients with possible polyneuropathy after adjuvant chemotherapy reported significantly lower quality of life than patients treated with surgery only. Conclusion: Symptoms of polyneuropathy following adjuvant docetaxel and oxaliplatin persist 5 years after treatment and affect quality of life negatively.",
keywords = "ASSOCIATION, COLON-CANCER, FLUOROURACIL, INDUCED PERIPHERAL NEUROPATHY, LEUCOVORIN, NEUROTOXICITY, OXALIPLATIN, PERSISTENT PAIN, QUALITY-OF-LIFE, SURVIVORS",
author = "Kristine Bennedsgaard and Lise Ventzel and Themistocleous, {Andreas C.} and Bennett, {David L.} and Jensen, {Anders B.} and Jensen, {Anni R.} and Andersen, {Niels T.} and Jensen, {Troels S.} and Hatice Tankisi and Finnerup, {Nanna B.}",
year = "2020",
month = jul,
doi = "10.1002/cam4.3129",
language = "English",
volume = "9",
pages = "5114--5123",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "JohnWiley & Sons Ltd.",
number = "14",

}

RIS

TY - JOUR

T1 - Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy

AU - Bennedsgaard, Kristine

AU - Ventzel, Lise

AU - Themistocleous, Andreas C.

AU - Bennett, David L.

AU - Jensen, Anders B.

AU - Jensen, Anni R.

AU - Andersen, Niels T.

AU - Jensen, Troels S.

AU - Tankisi, Hatice

AU - Finnerup, Nanna B.

PY - 2020/7

Y1 - 2020/7

N2 - Background: The aim of this study was to assess chemotherapy-induced polyneuropathy (CIPN) 5 years after adjuvant chemotherapy in patients with breast and colorectal cancer. The association of CIPN with quality of life, anxiety, and depression was analyzed. Methods: Of a set of 100 patients with breast cancer and of 74 with colorectal cancer who had undergone surgery and adjuvant chemotherapy in 2011-2012, 80 and 52 patients alive, respectively, were included together with two reference groups of 249 breast cancer patients and 83 colorectal cancer patients who had undergone surgery only. All patients were sent a questionnaire on alcohol consumption, smoking habits, comorbidity, medicine consumption, and oxaliplatin-specific questions, as well as the Michigan Neuropathy Screening Instrument questionnaire (MNSIq), the Douleur Neuropathique 4 Questions (DN4q), the EQ-5D, and the Hospital Anxiety and Depression Scale. Possible polyneuropathy was defined as the presence of numbness and/or tingling in the feet, secondly as a score of ≥4 on the MNSIq. Possible painful polyneuropathy was defined as pain in both feet and a score ≥3 on the DN4q. Results: The prevalence of possible polyneuropathy defined by numbness and/or tingling in the feet was 38.8% (28.1-50.3) after adjuvant docetaxel and 57.7% (43.2-71.3) after adjuvant oxaliplatin, with no significant difference from a previous 1-year follow-up (P >.35). Fewer had possible polyneuropathy as defined by the MNSIq. Patients with possible polyneuropathy after adjuvant chemotherapy reported significantly lower quality of life than patients treated with surgery only. Conclusion: Symptoms of polyneuropathy following adjuvant docetaxel and oxaliplatin persist 5 years after treatment and affect quality of life negatively.

AB - Background: The aim of this study was to assess chemotherapy-induced polyneuropathy (CIPN) 5 years after adjuvant chemotherapy in patients with breast and colorectal cancer. The association of CIPN with quality of life, anxiety, and depression was analyzed. Methods: Of a set of 100 patients with breast cancer and of 74 with colorectal cancer who had undergone surgery and adjuvant chemotherapy in 2011-2012, 80 and 52 patients alive, respectively, were included together with two reference groups of 249 breast cancer patients and 83 colorectal cancer patients who had undergone surgery only. All patients were sent a questionnaire on alcohol consumption, smoking habits, comorbidity, medicine consumption, and oxaliplatin-specific questions, as well as the Michigan Neuropathy Screening Instrument questionnaire (MNSIq), the Douleur Neuropathique 4 Questions (DN4q), the EQ-5D, and the Hospital Anxiety and Depression Scale. Possible polyneuropathy was defined as the presence of numbness and/or tingling in the feet, secondly as a score of ≥4 on the MNSIq. Possible painful polyneuropathy was defined as pain in both feet and a score ≥3 on the DN4q. Results: The prevalence of possible polyneuropathy defined by numbness and/or tingling in the feet was 38.8% (28.1-50.3) after adjuvant docetaxel and 57.7% (43.2-71.3) after adjuvant oxaliplatin, with no significant difference from a previous 1-year follow-up (P >.35). Fewer had possible polyneuropathy as defined by the MNSIq. Patients with possible polyneuropathy after adjuvant chemotherapy reported significantly lower quality of life than patients treated with surgery only. Conclusion: Symptoms of polyneuropathy following adjuvant docetaxel and oxaliplatin persist 5 years after treatment and affect quality of life negatively.

KW - ASSOCIATION

KW - COLON-CANCER

KW - FLUOROURACIL

KW - INDUCED PERIPHERAL NEUROPATHY

KW - LEUCOVORIN

KW - NEUROTOXICITY

KW - OXALIPLATIN

KW - PERSISTENT PAIN

KW - QUALITY-OF-LIFE

KW - SURVIVORS

UR - http://www.scopus.com/inward/record.url?scp=85085579347&partnerID=8YFLogxK

U2 - 10.1002/cam4.3129

DO - 10.1002/cam4.3129

M3 - Journal article

C2 - 32469145

AN - SCOPUS:85085579347

VL - 9

SP - 5114

EP - 5123

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 14

ER -